OMER insider trading
NasdaqGM HealthcareOMEROS CORP: insider trade history from SEC Form 4 filings.
About OMEROS CORP
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Company website: www.omeros.com
OMER insider activity at a glance
FilingIQ tracks 170 insider transactions for OMER in filings since Jan 29, 2015. The most recent transaction is dated Sep 23, 2026.
Across the full history, 3 open-market purchases
and 71 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on OMER insider trades is 60.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest OMER Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for OMER?
- FilingIQ tracks 170 Form 4 insider transactions for OMER (OMEROS CORP), covering filings from Jan 29, 2015 onwards. 25 of those are dated within the last 90 days.
- Are OMER insiders net buyers or net sellers?
- Across the full Form 4 history for OMER, 3 transactions (2%) were open-market purchases and 71 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does OMER insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is OMER in?
- OMEROS CORP (OMER) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $835.21M.
Methodology & sources
Every OMER insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.